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Cytomegalovirus (CMV) is the most frequent viral complication following hematopoietic cell 
transplantation (HCT).  Seronegative recipients who receive grafts from seropositive donors (D+/R-) 
are at risk for primary CMV transmission, as well as a higher incidence of non-CMV infections and 
increased mortality when compared to D-/R- HCT recipients. In order to better understand this type 
of primary CMV transmission, Dr. Steven Pergam and Dr. Michael Boeckh, along with collaborators 
in the Vaccine and Infectious Disease Division, studied risk factors associated with CMV 
transmission in D+/R- HCT recipients at the FHCRC. 
In this retrospective study, 447 CMV seronegative HCT recipients who received a transplant from a 
seropositive donor at FHCRC between 1995 and 2007 were evaluated, using clinical data and 
medical records from the first 100 days after HCT. Each patient was tested weekly using either the 
pp65 antigenemia assay, which quantifies the level of replicating virus by assessing antigen 
expression in leukocytes, or tested by PCR to monitor levels of CMV DNA. If patients did test 
positive, they began antiviral therapy. CMV transmission was detected in 85 of 447 (19%) of patients 
in the first year post-transplant. 76 primary infections occurred before day 100, with an additional 9 
between d100 and 1 year. 
 In risk factor analyses, patients with a higher number of total nucleated cells (TNC) in their graft (the 
upper fourth quartile) were at significantly higher risk for CMV transmission (HR 2.0, 95% CI, 1.2-
3.1). There was a trend toward an association with a higher risk of CMV transmission with a higher 
quartile of CD34 cells in the graft (HR 1.5, 95% CI, 0.9-2.6). Other cellular components were not 
shown to alter the risk of CMV acquisition, nor did the source stem cells, screening method, or 
GVHD. This study demonstrated that a highly cellular graft was the only risk factor associated with 
CMV transmission in D+/R- HCT recipients. The authors suggest that future studies evaluating donor 
immunity may lead to additional predictors of viral transmission that could be important in donor 
selection and risk assessment. 
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